From the Forum: Not Risk Factors for Lymphedema: Blood draws, IVs, BPs, Exercise, Air travel
Risk factors for Lymphedema: High BMI, Axillary dissection, Chemotherapy (esp taxanes), Radiation, Infection Not Risk Factors for Lymphedema: blood draws, IVs, ...
Cureus Competition Winner Announced!
In 2016, Cureus and TME sponsored a case report research competition called: Exceptional Responders in Breast cancer. We sought challenging cases where breast c...
Blood Test for Diagnosing Cancer #HolyGrail
Researchers at Johns Hopkins and their spin off company Personal Genome Diagnostics published a paper on their preliminary study of 138 early stage cancer patie...
Why John West M.D. is Passionate about Starting Mammography at "40not50"
BreastCareNetwork interviewed Breastlink founder Dr. John West about controversial breast screening guidelines and his ambitious new book aimed at providing all...
Prophylactic Mastectomy After BRCA+ Stage 2 Ovarian Ca: over 50? - No, under 50? - Consider after 5 yrs
A recent editorial in Annals of Surgical Oncology refines breast management decisions for BRCA+ patients who have been treated for ovarian cancer. Judy Boughey ...
AI Joint Pain Sucks - Easy Fix Found!
Aromatase inhibitor joint pain knocks more patients off treatment than any other side effect. Randomized study from UNC shows 150 min of easy walking per week i...
Ultralow-Risk Cancers do not Require Adjuvant Endocrine Therapy
June 29, 2017. Dr. Laura Esserman, Chief, Section of Breast Care Surgery at UCSF and Director, UCSF Carol Franc Buck Breast Care Center, published a new study i...
ASCO Biomarkers Guidelines Add MammaPrint - Including First ASCO Approval for Node Positive Patients
On July 10, 2017 ASCO published an update to its Breast Cancer Biomarkers Guidelines specifically to include Mammaprint (Agendia, Irvine, CA). The update author...
Her2 Status in Non Path Complete Responders to Neo-Adj Chemo
Spoiler alert - Her2 status can change after Neo-Adjuvant chemotherapy (NAC). In this retorspective study from Cedars Sinai, researchers identified 99 patients...
Targeted Therapy Wins Again #shocker
Patients with a TOPO-2 normal (not overexpressed) breast cancers do not benefit from adriamycin based adjuvant chemotherapy. Even though we are moving away fro...
